Resolved, That there shall be a special commission to evaluate and study the costs and benefits attributable to the usage of psychedelic drugs, which are currently being destroyed under section 47A of chapter 94C of the General Laws, for clinical trials and therapy. The special commission shall: (i) review the associated benefits of the use of psychedelic drugs in clinical trials; (ii) recommend appropriate regulations for such use; (iii) explore whether the use of psychedelic drugs may be expanded from clinical trials to standard therapeutic use; and (iv) recommend any changes to existing law regarding psychedelic drugs in the commonwealth.

The commission shall consist of: the house and senate chairs of the joint committee on mental health, substance use and recovery, who shall serve as co-chairs; the secretary of health and human services or a designee; the commissioner of public health or a designee; the director of the bureau of substance addiction services or a designee; 1 member of the senate who shall be appointed by the senate president; 1 member of the house of representatives who shall be appointed by the speaker of the house; and the executive director of the Massachusetts Organization for Addiction Recovery, Inc. or a designee. The special commission shall file its recommendations, including any proposed legislation, with the clerks of the senate and house of representatives not later than May 1, 2022